68Ga-FAPI与18F-FDG PET/CT在乳腺癌原发分期中的比较
这项前瞻性研究纳入50例乳腺癌患者,比较68Ga-FAPI PET/CT与18F-FDG PET/CT在原发分期中的诊断效能。结果显示68Ga-FAPI对原发灶及淋巴结转移的敏感度、特异度、准确率均高于18F-FDG,但配对分析未达统计学显著。68Ga-FAPI改变了6例患者的临床管理,需更大样本多中心研究进一步验证。
要点
- 68Ga-FAPI对乳腺原发灶的SUVmax显著高于18F-FDG,提示肿瘤显像更清晰。
- 68Ga-FAPI可检出18F-FDG阴性的肝转移灶,并显示更多骨转移病灶。
- 68Ga-FAPI改变12%患者的临床管理,在激素受体阳性及Grade 1肿瘤中SUVmax优势更明显。
核心结论
- 68Ga-FAPI PET/CT对乳腺原发灶、淋巴结转移及部分远处转移灶显示出有前景的诊断效能。
- 与18F-FDG PET/CT的配对比较未达统计学显著差异,但68Ga-FAPI为部分患者提供了额外的临床相关发现。
研究设计与样本
- 前瞻性研究,纳入50例乳腺癌患者,其中49例女性、1例男性,平均年龄54.56±13.73岁。
- 所有患者序贯接受18F-FDG PET/CT与68Ga-FAPI PET/CT检查用于分期评估。
- 以组织病理学结果作为参考标准,分析半定量68Ga-FAPI PET参数与病理指标的关系。
关键影像表现/征象
- 68Ga-FAPI对乳腺原发灶的平均SUVmax为13.32±7.1,显著高于18F-FDG的6.86±3.51。
- 68Ga-FAPI PET/CT在1例患者中显示更多骨骼转移灶,在另1例患者中检出18F-FDG阴性的肝转移。
- 在激素受体阳性和Grade 1肿瘤等亚组中,68Ga-FAPI的SUVmax值显著高于18F-FDG。
诊断标准与关键数值
- 原发灶检出敏感度:68Ga-FAPI为100%(95%CI 92.9-100.0),18F-FDG为92%(95%CI 80.4-100),McNemar p=0.0625。
- 原发灶阳性预测值:两种显像剂均为100%(95%CI 92.9-100.0)。
- 淋巴结转移患者基础敏感度:68Ga-FAPI为72.4%(95%CI 52.8-87.3),18F-FDG为60.7%(95%CI 40.6-78.5),McNemar p=0.125。
- 淋巴结转移患者基础特异度:68Ga-FAPI为95.2%(95%CI 76.2-99.9),18F-FDG为85.7%(95%CI 63.7-97.0),McNemar p=0.50。
- 淋巴结转移患者基础准确率:68Ga-FAPI为82.0%(95%CI 68.6-91.4),18F-FDG为71.4%(95%CI 56.7-83.4)。
临床应用与阅片要点
- 68Ga-FAPI在乳腺原发灶和淋巴结转移的显像对比度优于18F-FDG,尤其在低级别和激素受体阳性肿瘤中。
- 当18F-FDG PET/CT结果为阴性但临床高度怀疑转移时,可考虑68Ga-FAPI PET/CT作为补充手段。
- 腋窝淋巴结SUVmean和TLU与原发肿瘤Ki-67呈正相关,可间接反映肿瘤增殖活性。
局限性
- 原发灶及淋巴结转移的敏感度、特异度等配对比较均未达到统计学显著性。
- 亚组分析中两种显像剂的检出率差异同样未达到统计学显著性。
- 原文指出需要更大规模的多中心研究来进一步明确其临床定位。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the role of 68Ga-FAPI PET/CT in primary staging of breast cancer in comparison with 18F-FDG PET/CT.
METHODS: In this prospective study, 50 breast cancer patients (49F,1M, age:54.56 ± 13.73) were included. 18F-FDG PET/CT and 68Ga-FAPI PET/CT were performed consecutively for staging purposes. Patient-based sensitivity, specificity, PPV, NPV and accuracy were calculated. Relationship between semiquantitative 68Ga-FAPI PET parameters and histopathology were analysed.
RESULTS: Patient based sensitivity for detection of primary breast lesions of 68Ga-FAPI were higher than 18F-FDG PET/CT (100 % (95 % CI: 92.9-100.0) vs 92 % (95 % CI: 80.4-100)), although not reached statistical significance (exact McNemar p = 0.0625). PPV was 100 % (95 % CI: 92.9-100.0) for both modalities. For lymph node metastases, patient-based sensitivity, specificity, PPV, NPV and accuracy of 68 Ga-FAPI PET/CT were 72.4 % (95 % CI: 52.8-87.3), 95.2 % (95 % CI: 76.2-99.9), 95.5 % (95 % CI: 77.2-99.9), 71.4 % (95 % CI: 51.3-86.8) and 82.0 % (95 % CI: 68.6-91.4), respectively, whereas those of 18F-FDG PET/CT were 60.7 % (95 % CI: 40.6-78.5), 85.7 % (95 % CI: 63.7-97.0), 85.0 % (95 % CI: 62.1-96.8), 62.1 % (95 % CI: 42.3-79.3) and 71.4 % (95 % CI: 56.7-83.4), respectively (for sensitivity and specificity, exact McNemar p = 0.125 and p = 0.50). Mean SUVmax of 68Ga FAPI uptake of primary breast lesions were significantly higher than 18F-FDG uptake (13.32 ± 7.1 vs 6.86 ± 3.51p < 0.001). Ki-67 of the primary tumors was correlated with SUVmean and TLU of axillary lymph nodes (r = 0.64,p = 0.006 and r = 0.66,p = 0.004). PR positivity and TV of the breast lesions were inversely correlated (r = -0.32,p = 0.044). There were 4 patients with distant metastasis: skeletal metastases in 3 patients and liver metastasis in one patient. 68Ga-FAPI showed greater number of skeletal metastasis in 1 patient and revealed an 18F-FDG negative liver metastasis in another patient. 68Ga-FAPI PET/CT changed management in 6 patients (12 %). Exploratory subgroup analyses demonstrated that 68Ga-FAPI PET/CT maintained a 100 % detection rate across all evaluated biological subgroups, whereas the detectability of 18F-FDG PET/CT varied according to tumor biology, with the lowest detection rate observed in Grade 1 tumors; paired subgroup comparisons using the exact McNemar test did not demonstrate statistically significant differences in detectability rates, although 68Ga-FAPI PET/CT showed significantly higher SUVmax values in several biological subgroups, particularly in hormone receptor-positive and Grade 1 tumors.
CONCLUSION: 68Ga-FAPI PET/CT demonstrated promising diagnostic performance for the detection of primary breast tumors, lymph node metastases, and selected distant metastatic lesions. Although paired statistical analysis did not demonstrate significant differences compared with 18F-FDG PET/CT, 68Ga-FAPI PET/CT provided additional clinically relevant findings in a subset of patients. Larger multicenter studies are needed to further define its clinical role in breast cancer staging.
引用
- Araz, Soydal, Konca, et al. Comparison of 68ga fapi pet/ct and 18f-fdg pet/ct in primary staging of breast cancer. Eur J Radiol. 2026. PMID: 42710423. doi:10.1016/j.ejrad.2026.113222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。